Clinical Trial Search

Primary: Haemostatic Effect During Surgery Evaluated by the Four-point Scale, Assessed by the Investigator/Surgeon at the Day of Surgery - Four-point Response Scale: Excellent…

Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01

Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) — 4.8; 11.4; 16.8…

Primary: For the US FDA: The Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 12 Hours After First Intake of Investigational Medicinal Product (IMP)…

Primary: Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 6 — -9.1…

Primary: Number of Participants With Treatment Emergent Adverse Event (TEAEs) — 64 Participants

Primary: The Incidence of Overall Adverse Events, AEs , Serious Adverse Envents,(or SAEs), and AEs (or SAEs) Leading to Discontinuation — 144; 30; 3; 1 adverse events

Primary: Number of Participants With Clinical Response During Double-Blind Acute Phase at Week 8 — 10; 17 Participants — p=0.039

Primary: Recurrence-free Survival — 80; 96 Participants

Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001

Primary: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score — 2.99; 3.26 score on a scale

Primary: Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups — 10; 14 percentage of infusions with IRRs — p=0.1996

Primary: Complete Clearance of AK Lesions — 45; 44; 7 Participants

Primary: Relapse-free Survival (RFS) — 2.1; 1.3 years